SG11201810871WA - Methods of producing modified natural killer cells and methods of use - Google Patents

Methods of producing modified natural killer cells and methods of use

Info

Publication number
SG11201810871WA
SG11201810871WA SG11201810871WA SG11201810871WA SG11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA
Authority
SG
Singapore
Prior art keywords
cells
methods
international
bethesda
population
Prior art date
Application number
SG11201810871WA
Other languages
English (en)
Inventor
Richard Childs
Dhanalakshmi Chinnasamy
David Allan
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of SG11201810871WA publication Critical patent/SG11201810871WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1135—Granulocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201810871WA 2016-07-25 2017-07-25 Methods of producing modified natural killer cells and methods of use SG11201810871WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366493P 2016-07-25 2016-07-25
PCT/US2017/043774 WO2018022646A1 (en) 2016-07-25 2017-07-25 Methods of producing modified natural killer cells and methods of use

Publications (1)

Publication Number Publication Date
SG11201810871WA true SG11201810871WA (en) 2019-01-30

Family

ID=59656171

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810871WA SG11201810871WA (en) 2016-07-25 2017-07-25 Methods of producing modified natural killer cells and methods of use
SG11202003201QA SG11202003201QA (en) 2016-07-25 2018-11-01 Methods of producing modified natural killer cells and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202003201QA SG11202003201QA (en) 2016-07-25 2018-11-01 Methods of producing modified natural killer cells and methods of use

Country Status (7)

Country Link
US (2) US11293010B2 (de)
EP (2) EP3487991B1 (de)
JP (2) JP7086928B2 (de)
CN (2) CN109844099B (de)
IL (1) IL273979B1 (de)
SG (2) SG11201810871WA (de)
WO (2) WO2018022646A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
WO2016077734A2 (en) * 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
CN109844099B (zh) * 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) 产生经修饰的自然杀伤细胞的方法及使用方法
WO2018104554A1 (en) * 2016-12-09 2018-06-14 Onkimmune Limited Improved nk-based cell therapy
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
CN111757745B (zh) 2018-02-01 2022-11-04 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
SG11202007156QA (en) * 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019165097A1 (en) * 2018-02-21 2019-08-29 Board Of Regents,The University Of Taxas System Universal antigen presenting cells and uses thereof
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
WO2019222503A1 (en) * 2018-05-16 2019-11-21 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
US20210261645A1 (en) * 2018-05-23 2021-08-26 Manysmart Therapeutics, Inc. Bispecific t cell engager and uses thereof
WO2019229109A1 (en) * 2018-05-30 2019-12-05 Glycostem Therapeutics B.V. Car nk cells
EP3802795A4 (de) * 2018-06-06 2022-03-16 Stemcell Technologies Canada Inc. Kits, zusammensetzungen und verfahren zur anreicherung von suppressorzellen aus knochenmark
CA3106324C (en) 2018-08-01 2024-04-02 Nantkwest, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
JP7399157B2 (ja) * 2018-08-28 2023-12-15 北京永泰瑞科生物科技有限公司 改良された治療用ｔ細胞
US20220042039A1 (en) * 2018-08-28 2022-02-10 Pharos Vaccine Inc. Improved lentiviral vector
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
US20210348196A1 (en) * 2018-10-10 2021-11-11 Wisconsin Alumni Research Foundation Kir 7.1 gene therapy vectors and methods of using the same
CN109402053A (zh) * 2018-10-17 2019-03-01 广州元帅生物科技有限公司 一种外周血来源单个核细胞的分离及诱导培养方法
WO2020172328A1 (en) * 2019-02-20 2020-08-27 Rutgers, The State University Of New Jersey Expansion of natural killer and chimeric antigen receptor-modified cells
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3938387A1 (de) 2019-03-15 2022-01-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Chimäre adapter- und kinasesignalproteine und ihre verwendung in der immuntherapie
KR20200110576A (ko) * 2019-03-15 2020-09-24 재단법인대구경북과학기술원 사이토카인 기반 면역세포 및 그의 면역 치료 용도
EP3712257A1 (de) * 2019-03-21 2020-09-23 ONK Therapeutics Limited Modifizierte natürliche killerzellen mit erhöhter resistenz gegen zelltod
US20220143089A1 (en) * 2019-03-21 2022-05-12 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
CN110079529A (zh) * 2019-04-28 2019-08-02 成都美杰赛尔生物科技有限公司 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途
CN110106202A (zh) * 2019-05-07 2019-08-09 杭州师范大学 抗肿瘤nk细胞的制备方法及其细胞与应用
CN110205293A (zh) * 2019-06-25 2019-09-06 中冠赛尔生物科技(北京)有限公司 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用
WO2021051088A1 (en) * 2019-09-13 2021-03-18 Ohio State Innovation Foundation Nk cell immunotherapy compositions, methods of making and methods of using same
US20210077527A1 (en) * 2019-09-13 2021-03-18 The Research Institute At Nationwide Children's Hospital Universal donor selection method to identify nk-cell-donors
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
US20230190800A1 (en) 2020-03-26 2023-06-22 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Cd28h domain-containing chimeric antigen receptors and methods of use
WO2022007796A1 (zh) * 2020-07-06 2022-01-13 上海鑫湾生物科技有限公司 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用
CN112029721A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种活性增强型nk细胞的制备方法
KR102581230B1 (ko) * 2020-10-16 2023-09-21 의료법인 성광의료재단 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도
EP4240829A1 (de) 2020-11-04 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Modifizierte nk-zellen mit reduzierter ccr5-expression und verfahren zu deren verwendung
WO2023034729A1 (en) * 2021-08-30 2023-03-09 Carrygenes Bioengineering, Llc Safety switches for engineered cells carrying synthetic chromosomes
WO2023044304A1 (en) 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
CN114306606B (zh) * 2021-11-29 2023-05-26 江苏省人民医院（南京医科大学第一附属医院） cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用
CN114381434A (zh) * 2022-01-17 2022-04-22 华东师范大学 一种趋化型car-nk细胞及其制备方法和应用
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用
CN115074325A (zh) * 2022-07-07 2022-09-20 广州希灵生物科技有限公司 Herceptin联合4-1BBL体外扩增NK方法
CN115466726B (zh) * 2022-09-05 2023-09-19 北京景达生物科技有限公司 一种nk细胞的高效基因转导方案

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
DE10019075B4 (de) * 2000-04-18 2007-01-18 Vision 7 Gmbh Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
CN101356679A (zh) * 2005-10-31 2009-01-28 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物和方法
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
CN101684456A (zh) * 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
SG176890A1 (en) * 2009-06-17 2012-01-30 Tocagen Inc Producer cells for replication competent retroviral vectors
CN112430580A (zh) * 2012-10-02 2021-03-02 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
EP2793026A1 (de) * 2013-04-18 2014-10-22 Centre National de la Recherche Scientifique (CNRS) Neues Verfahren zur Überwachung von Krebs und/oder der Entzündungsreaktion auf Grundlage der RelB-Phosphorylierung
MX370173B (es) * 2013-05-03 2019-12-04 Ohio State Innovation Foundation Células efectoras inmunitarias modificadas genéticamente con el receptor de antígenos quiméricos específico de cs1.
US20170029777A1 (en) * 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
WO2016077734A2 (en) 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
US10815457B2 (en) * 2014-11-24 2020-10-27 University Of Pittsburgh Of The Commonwealth Systems Of Higher Education Active CXCR4+ immune cells and methods for their production and use
EP3356524B1 (de) * 2015-09-30 2021-08-18 Vycellix, Inc. Verbesserte genverabreichung an natürliche killerzellen, hämatopoetische stammzellen und makrophagen
CN105567634A (zh) * 2016-01-27 2016-05-11 上海润泉生物技术有限公司 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法
US20200392457A1 (en) * 2016-07-25 2020-12-17 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods of producing modified natural killer cells and methods of use
CN109844099B (zh) 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) 产生经修饰的自然杀伤细胞的方法及使用方法
CN106350487B (zh) * 2016-09-13 2019-01-25 北京多赢时代转化医学研究院 联合制备car-nk细胞和car-nkt细胞的方法
WO2018098279A1 (en) * 2016-11-22 2018-05-31 Alloplex Biotherapeutics Allogenic tumor cell vaccine

Also Published As

Publication number Publication date
EP3704231A1 (de) 2020-09-09
JP7364559B2 (ja) 2023-10-18
IL273979B1 (en) 2024-05-01
EP3487991A1 (de) 2019-05-29
JP2019523001A (ja) 2019-08-22
JP2021501578A (ja) 2021-01-21
US11293010B2 (en) 2022-04-05
EP3487991B1 (de) 2022-09-07
JP7086928B2 (ja) 2022-06-20
WO2019089955A1 (en) 2019-05-09
CN109844099A (zh) 2019-06-04
US20180057795A1 (en) 2018-03-01
CN109844099B (zh) 2024-01-02
US20220228117A1 (en) 2022-07-21
CN111344395A (zh) 2020-06-26
WO2018022646A1 (en) 2018-02-01
SG11202003201QA (en) 2020-05-28
IL273979A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
SG11201810871WA (en) Methods of producing modified natural killer cells and methods of use
SG11201806002SA (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201908658TA (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201811432WA (en) Rna for cancer therapy
SG11201903407XA (en) Secretable variant immunomodulatory proteins and engineered cell therapy
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201807269PA (en) Filamentous fungal biomats, methods of their production and methods of their use
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201907319QA (en) Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
SG11201807134RA (en) Transposon system and methods of use
SG11201809993VA (en) Oncolytic viruses comprising esrage and methods of treating cancer
SG11201805001UA (en) Method of treating influenza a